Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review

被引：0
|
作者：
Nicolas Vandenbussche
Karolina Pisarek
Koen Paemeleire
机构：
[1] Ghent University Hospital,Department of Neurology
[2] Ghent University,Faculty of Medicine and Health Sciences
来源：
The Journal of Headache and Pain | / 24卷
关键词：
Methodology; Migraine; CGRP; Real-world evidence; Clinical trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine
    Mechtler, L. L.
    Saikali, N. P.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    HEADACHE, 2021, 61 : 176 - 177
  • [32] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey Manack
    FRONTIERS IN NEUROLOGY, 2022, 12
  • [33] Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
    Krymchantowski, Abouch V. V.
    Jevoux, Carla
    Krymchantowski, Ana Gabriela
    Silva-Neto, Raimundo Pereira
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [34] Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
    Siersbaek, Nikolaj
    Kilsdal, Laerke
    Jervelund, Christian
    Antic, Sonja
    Bendtsen, Lars
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 1 - 2
  • [35] Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
    Nikolaj Siersbæk
    Lærke Kilsdal
    Christian Jervelund
    Sonja Antic
    Lars Bendtsen
    BMC Neurology, 23
  • [36] Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
    Siersbaek, Nikolaj
    Kilsdal, Laerke
    Jervelund, Christian
    Antic, Sonja
    Bendtsen, Lars
    BMC NEUROLOGY, 2023, 23 (01)
  • [37] REAL-WORLD EVIDENCE FOR CONTROL OF PATIENTS WITH CHRONIC MIGRAINE WHO RECEIVED CGRP MONOCLONAL ANTIBODY THERAPY ADDED TO ONABOTULINUMTOXINA TREATMENT
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Schneider, Gary
    Yedigarova, Larisa
    Adams, Aubrey Manack
    CEPHALALGIA, 2020, 40 : 96 - 97
  • [38] Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis
    Messina, Roberta
    Huessler, Eva-Maria
    Puledda, Francesca
    Haghdoost, Faraidoon
    Lebedeva, Elena R.
    Diener, Hans-Christoph
    CEPHALALGIA, 2023, 43 (03)
  • [39] Clinical practice in prevention of migraine with calcitonin-gene related peptide monoclonal antibodies: real-world evidence
    Castano-Amores, Celia
    Nieto-Gomez, Pelayo
    Teresa Nieto-Sanchez, Maria
    Alvarez-Sanchez, Raquel
    ARS PHARMACEUTICA, 2022, 63 (04) : 311 - 319
  • [40] Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review
    Murray, Ann M.
    Stern, Jennifer I.
    Robertson, Carrie E.
    Chiang, Chia-Chun
    CURRENT PAIN AND HEADACHE REPORTS, 2022, 26 (10) : 783 - 794
12345